Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-04-08 00:07 | 2017-04-05 | BTU | PEABODY ENERGY CORP | ELLIOTT INTERNATIONAL, L.P. | 10% owner | Bituminous Coal & Lignite Surface Mining | BUY | $27.82 | 369,240 | $10,273,549 | 8,555,551 | +4.5% |
| 2017-04-08 00:07 | 2017-04-05 | BTU | PEABODY ENERGY CORP | ELLIOTT ASSOCIATES, L.P. | 10% owner | Bituminous Coal & Lignite Surface Mining | BUY | $27.82 | 173,760 | $4,834,611 | 1,197,187 | +17.0% |
| 2017-04-06 21:49 | 2017-04-04 | GLO | Clough Global Opportunities Fund | Saba Capital Management, L.P. | 10% owner | Other | BUY | $10.23 | 215,281 | $2,202,691 | 5,740,263 | +3.9% |
| 2017-04-07 00:38 | 2017-04-04 | APO | Apollo Global Management Inc. | TIGER GLOBAL MANAGEMENT LLC | 10% owner | Investment Advice | BUY | $25.03 | 403,200 | $10,092,660 | 23,764,999 | +1.7% |
| 2017-04-06 00:34 | 2017-04-04 | N/A | N/A | Packer Craig | Director, Officer - President and CEO | Other | BUY | $9.00 | 116,667 | $1,050,000 | 116,667 | +100.0% |
| 2017-04-04 17:29 | 2017-03-31 | JFC | N/A | Bulldog Investors, LLC | 10% owner | Other | BUY | $18.40 | 83,599 | $1,537,937 | 585,455 | +16.7% |
| 2017-04-04 01:56 | 2017-03-30 | APO | Apollo Global Management Inc. | TIGER GLOBAL MANAGEMENT LLC | 10% owner | Investment Advice | BUY | $23.75 | 361,800 | $8,594,161 | 23,361,799 | +1.6% |
| 2017-04-03 16:19 | 2017-03-31 | CARA | Tvardi Therapeutics, Inc. | RHO Ventures VI LP | 10% owner | Pharmaceutical Preparations | BUY | $18.19 | 500,000 | $9,095,700 | 3,568,057 | +16.3% |
| 2017-03-31 22:02 | 2016-09-06 | BTGI | N/A | Shapiro Gary L | Officer, 10% owner - President of Subsidiary | Other | BUY | $204,823.41 | 67,950,000 | $13,917,750,750,270 | 0 | +100.0% |
| 2017-04-01 01:53 | 2017-03-29 | AYX | N/A | ICONIQ STRATEGIC PARTNERS II, L.P. | 10% owner | Other | BUY | $14.00 | 675,000 | $9,450,000 | 296,382 | +100.0% |
| 2017-03-31 20:04 | 2017-03-30 | CPB | CAMPBELL'S Co | DORRANCE BENNETT | Director, 10% owner | Food and Kindred Products | BUY | $57.34 | 915,766 | $52,510,022 | 1,386,643 | +194.5% |
| 2017-04-01 03:13 | 2017-03-22 | MULE | N/A | Bain Capital Public Equity Management, LLC | 10% owner | Other | BUY | $25.06 | 203,082 | $5,089,397 | 703,082 | +40.6% |
| 2017-03-30 16:32 | 2017-03-28 | ICCH | N/A | Clinton Richard Kevin | Director, 10% owner | Other | BUY | $10.00 | 600,000 | $6,000,000 | 75,000 | +100.0% |
| 2017-03-31 03:14 | 2017-03-28 | VLRX | N/A | Capital Royalty L.P. | 10% owner | Other | BUY | $10.00 | 4,000,000 | $40,000,000 | 1,066,390 | +100.0% |
| 2017-03-31 00:12 | 2017-03-28 | CLR | N/A | Hamm Harold | Director, Officer, 10% owner - CEO & Chairman | Other | BUY | $42.90 | 32,985 | $1,414,954 | 1,044,092 | +3.3% |
| 2017-03-31 00:47 | 2017-03-28 | FSC | Oaktree Specialty Lending Corp | TANNENBAUM LEONARD M | 10% owner | Other | BUY | $4.74 | 368,073 | $1,744,261 | 15,614,816 | +2.4% |
| 2017-03-30 21:05 | 2017-03-28 | IRLD | N/A | NANOMINERALS CORP. | 10% owner | Other | BUY | $0.08 | 21,250,000 | $1,700,000 | 62,400,000 | +51.6% |
| 2017-03-30 22:59 | 2017-03-17 | MULE | N/A | Bain Capital Public Equity Management, LLC | 10% owner | Other | BUY | $19.33 | 703,082 | $13,589,239 | 703,082 | +100.0% |
| 2017-03-29 17:53 | 2017-02-21 | PFLEX | PIMCO Flexible Credit Income Fund Class A-4 | Allianz Fund Investments, Inc. | 10% owner | Other | BUY | $10.00 | 290,000 | $2,900,000 | 300,000 | +2,900.0% |
| 2017-03-30 01:08 | 2017-03-28 | ICCH | N/A | Klockau John R. | Director - Board of Directors | Other | BUY | $10.00 | 115,000 | $1,150,000 | 115,000 | +100.0% |
| 2017-03-29 23:13 | 2017-03-28 | AVEO | N/A | Viswanathan Ravi | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:12 | 2017-03-28 | AVEO | N/A | Sonsini Peter W. | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:11 | 2017-03-28 | AVEO | N/A | Sakoda Jon | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:10 | 2017-03-28 | AVEO | N/A | Florence Anthony A. Jr. | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:09 | 2017-03-28 | AVEO | N/A | Growth Equity Opportunities IV, LLC | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:10 | 2017-03-28 | AVEO | N/A | BASKETT FOREST | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:12 | 2017-03-28 | AVEO | N/A | SANDELL SCOTT D | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:10 | 2017-03-28 | AVEO | N/A | MAKOWER JOSHUA | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:11 | 2017-03-28 | AVEO | N/A | MOTT DAVID M | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 23:09 | 2017-03-28 | AVEO | N/A | BARRIS PETER J | 10% owner | Other | BUY | $0.50 | 6,000,000 | $3,000,000 | 16,362,694 | +57.9% |
| 2017-03-29 00:36 | 2017-03-27 | NGHC | N/A | Karfunkel Barry | Director, Officer - CEO and President | Other | BUY | $22.87 | 49,978 | $1,142,772 | 53,473 | +1,430.0% |
| 2017-03-28 23:24 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | Florence Anthony A. Jr. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-28 23:27 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | Sonsini Peter W. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-28 23:19 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | New Enterprise Associates 14, L.P. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-28 23:27 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | Viswanathan Ravi | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-29 02:18 | 2017-03-28 | KTEC | N/A | PVAM Perlus Microcap Fund, L.P. | 10% owner | Other | BUY | $13.10 | 80,500 | $1,054,550 | 617,359 | +15.0% |
| 2017-03-29 01:54 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | Thompson Peter A. | Director | Biological Products, (No Diagnostic Substances) | BUY | $4.20 | 1,190,476 | $4,999,999 | 6,149,377 | +24.0% |
| 2017-03-29 00:23 | 2017-03-24 | CLR | N/A | Hamm Harold | Director, Officer, 10% owner - CEO & Chairman | Other | BUY | $42.37 | 41,998 | $1,779,455 | 1,011,107 | +4.3% |
| 2017-03-28 23:08 | 2017-03-24 | N/A | N/A | Golub Lawrence E | Director, Officer - Chairman | Other | BUY | $15.00 | 67,354 | $1,010,303 | 1,147,992 | +6.2% |
| 2017-03-28 23:07 | 2017-03-24 | N/A | N/A | Golub David | Director, Officer - President and CEO | Other | BUY | $15.00 | 67,354 | $1,010,303 | 1,147,992 | +6.2% |
| 2017-03-28 23:23 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | BASKETT FOREST | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-29 03:06 | 2017-03-24 | VSAR | Aravive, Inc. | AKKARAJU SRINIVAS | Director | Pharmaceutical Preparations | BUY | $12.25 | 571,429 | $7,000,005 | 571,429 | +100.0% |
| 2017-03-28 23:26 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | SANDELL SCOTT D | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-28 23:24 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | KERINS PATRICK J | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-28 23:17 | 2017-03-24 | F | FORD MOTOR CO | FORD WILLIAM CLAY JR | Director, Officer - Exec. Chairman and Chairman | Motor Vehicles & Passenger Car Bodies | BUY | $11.67 | 171,379 | $1,999,993 | 8,958,397 | +2.0% |
| 2017-03-28 23:25 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | MOTT DAVID M | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-28 23:21 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | BARRETT M JAMES | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
| 2017-03-29 00:05 | 2017-03-24 | BLCM | N/A | BAKER BROS. ADVISORS LP | 10% owner | Other | BUY | $12.00 | 166,666 | $1,999,992 | 4,527,089 | +3.8% |
| 2017-03-29 01:48 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | ORBIMED ADVISORS LLC | Director | Biological Products, (No Diagnostic Substances) | BUY | $4.20 | 1,190,476 | $4,999,999 | 6,149,377 | +24.0% |
| 2017-03-28 23:22 | 2017-03-27 | ADAP | Adaptimmune Therapeutics PLC | BARRIS PETER J | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $0.70 | 12,870,000 | $9,009,000 | 72,139,000 | +21.7% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.